Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This is an observational study to describe the treatment patterns and clinical outcomes
observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's
disease patients experiencing "off" episodes with motor fluctuations
Phase
Phase IV
Funding Agency/Sponsor
Industry
Disease
Movement Disorders
Enrollment Eligibility
Inclusion Criteria:
- Must be able to complete electronic patient-reported outcome instruments
- Parkinson's disease patients experiencing "off" episodes
- Patient receiving concomitant levodopa/carbidopa, and as deemed appropriate by the
physician, newly initiating ONGENTYS as adjunctive treatment
Exclusion Criteria:
- Patient is not cognitively able to complete the study requirements
- Patient is not able to complete the study duration of 6 months
- History of moderate or severe hepatic impairment
- Patient has end-stage renal disease
- Concomitant use of non-selective monoamine oxidase (MAO) inhibitor or
catechol-O-methyltransferase (COMT) inhibitors (patients entering study may switch
from other COMT inhibitors to ONGENTYS)
- History of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasms
- Currently enrolled in an interventional clinical trial
- Currently or previously received ONGENTYS